RecruitingHR+/HER2- Breast Cancer

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Eligible age

18+ yrs

Accepts

All genders

Locations

27 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.

Sponsor: BeOne Medicines

You may qualify if…

✓ Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent.
✓ Participants with histologically confirmed locally advanced or metastatic HR+ HER2- breast cancer.
✓ Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
✓ Adequate organ function.

You may not qualify if…

✕ Participants who have received prior systemic treatment in the advanced or metastatic setting.
✕ Participants who have received prior treatment with any selective cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 2 (CDK2) targeting agent, or any other investigational anticancer drug in any disease setting, except for prior investigational or approved SERDs in the adjuvant setting, provided that disease recurrence occurred more than 12 months after the last dose of endocrine-based therapy.
✕ Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis.
✕ Note: Other protocol-defined inclusion/exclusion criteria may apply.